Nobel Prize in Physiology or Medicine for Hepatitis C Virus Discovery
The 2020 Nobel Prize in Physiology or Medicine was awarded jointly to Harvey J. Alter, Michael Houghton, and Charles M. Rice for their discovery of the hepatitis C virus. 1, 2, 3
The Three Laureates and Their Contributions
Harvey J. Alter
- Demonstrated the existence of a new blood-borne virus responsible for the majority of post-transfusion hepatitis cases that were neither hepatitis A nor hepatitis B 1, 2
- Conducted systematic clinical studies in the 1970s that proved a distinct infectious agent was causing what was then called "non-A, non-B hepatitis" 1
- His work laid the epidemiological foundation showing this was a transfusion-associated infection with significant public health implications 4
Michael Houghton
- Successfully cloned the hepatitis C virus using molecular biology techniques in 1989 1, 2
- Isolated a portion of the viral genome from the plasma of a chimpanzee with chronic non-A, non-B hepatitis 5
- Developed the first blood test to identify carriers of the virus, enabling screening of blood donations and preventing transmission 1, 6
- The original clone (clone 5-1-1) was derived from a single-stranded RNA molecule and led to development of diagnostic assays 5
Charles M. Rice
- Provided definitive proof that HCV alone could cause hepatitis 1, 2
- Demonstrated through molecular biology techniques that a cloned HCV could produce long-standing infection and cause the same disease observed in humans 1
- His work completed the scientific proof of causation, fulfilling Koch's postulates for this viral infection 4
Impact on Global Health
The combined work of these three researchers has had transformative effects:
- Enabled development of sensitive blood tests that virtually eliminated post-transfusion hepatitis 2, 6
- Led to direct-acting antiviral agents that can cure more than 95% of HCV infections with minimal side effects 6, 4
- Saved millions of lives by providing the foundation for diagnosis, prevention, and treatment 3, 4
- Created the possibility of global HCV elimination by 2030, as targeted by the World Health Organization 3, 6
The discovery represents approximately 700,000 deaths prevented annually worldwide from chronic hepatitis C and its complications including cirrhosis and hepatocellular carcinoma 4.